Study study type PathologyT1T0Patientssample sizesROB Results

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus Ipilimumab (10 mg/kg)
nivolumab alone
CheckMate 238, 2017
  NCT02388906
RCTmML - NA - all populationnivolumabipilimumabpatient, 15 years of age or older, with high-risk resected stage IIIB, IIIC, or IV melanoma as adjuvant treatment453 / 453low
conclusif
  • demonstrated 35 % decrease in RFS/DFS (PE)
  • suggested 27 % decrease in MFS
  • suggested 29 % decrease in RFS (extension)
versus placebo
nivolumab alone
IMMUNED (N vs P ; all population), 2020
  NCT02523313
RCTmML - NA - all populationnivolumabplaceboadjuvant therapy with nivolumab alone or in combination with ipilimumab compared with placebo in patients with stage IV melanoma with no evidence of disease59 / 52low
conclusif
  • demonstrated 44 % decrease in RFS/DFS (PE)
pembrolizumab alone
KEYNOTE 054 (all population), 2018
  NCT02362594
RCTmML - NA - all populationpembrolizumabplacebopatients with complete Resection of High-Risk Stage III Melanoma, stage IIIA, IIIB or IIIC melanoma with no in-transit metastases,514 / 505low
conclusif
  • demonstrated 43 % decrease in RFS/DFS (PE)
  • suggested 47 % decrease in MFS
  • suggested 44 % decrease in RFS (extension)
  • suggested 41 % decrease in RFS (extension)
  • more...